Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA7 | P43166 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15632424 | 0.83 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31387954 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29162628 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31387952 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8495483 | 0.81 | GAA (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24773853 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31387953 | 0.81 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4635236 | 0.80 | GABRP (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL502007 | 0.80 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15814434 | 0.78 | CA12 (0.41) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109794215-B | Continuous device for chlorohydroxypyridine and method for continuously chlorohydroxypyridine | 凯莱英医药集团（天津）股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-109794215-A | The method of continuous device and continuous chlorination pyridone substance for chlorination pyridone substance | 凯莱英医药集团（天津）股份有限公司 | 2019-05-24 | — | — | CN | claimed |
| CN-109794215-B | Continuous device for chlorohydroxypyridine and method for continuously chlorohydroxypyridine | 凯莱英医药集团（天津）股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-209985424-U | Continuous device for chlorinating hydroxypyridine substances | 凯莱英医药集团（天津）股份有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-109794215-A | The method of continuous device and continuous chlorination pyridone substance for chlorination pyridone substance | 凯莱英医药集团（天津）股份有限公司 | 2019-05-24 | — | — | CN | disclosed |
| WO-2019008308-A1 | POLARISATION TRANSFER VIA A SECOND METAL COMPLEX | UNIVERSITY OF YORK (GB) | 2019-01-10 | — | — | WO | disclosed |
| EP-3052494-B1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006105023-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217417-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-0909270-B1 | PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE | AVENTIS PHARM PROD INC (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6392049-B1 | NITRATION USING NITRIC ACID | AVENTIS PHARMACEUTICALS INC. | 2002-05-21 | — | — | US | disclosed |
| US-6307054-B1 | HEATING A 5-CARBOXY-2,4-DIHYROXYPYRIDINE AND PHOSPHORIC ACID WHERE THE RATIO OF PHOSPHORIC ACID TO WATER IS NOT LESS THAN ABOUT 27 TO 1 WEIGHT %. | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0909270-A4 | — | — | 1999-04-21 | — | — | EP | disclosed |
| EP-0909270-A1 | PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1997024327-A1 | PROCESS FOR PREPARING 2,4-DIHYDROXYPYRIDINE AND 2,4-DIHYDROXY-3-NITROPYRIDINE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217417-A1 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCQ, PRKCH, PRKCZ | CA12 4055/4885CA1 2675/4885CA2 1370/4885 |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | CA12 4643/4885CA1 4853/4885CA2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.